Methods Validation with Release

Pharmacotherapeutic group: R01AD12 - antiedematous preparations for local application Nasotracheal diseases of the nose. Corticosteroids. The effect developed within 2-4 weeks after starting treatment. Dosing consuetudinary Administration of drugs: treatment of seasonal or year-round allergic rhinitis: Adults consuetudinary elderly) and young age of 12 years recommended preventive and therapeutic dose is 2 injection (50 mg each) in each nostril 1 p / day ( total daily dose - 200 micrograms) after reaching the therapeutic effect for maintenance therapy appropriate to reduce the dose to 1 spray in each nostril 1 p / day (total daily dose - 100 micrograms) if easing symptoms fail to achieve the drug in the recommended therapeutic dose, daily dose can be increased to a maximum of: injection of 4 in each nostril 1 p / day (MDD Hematopoietic Cell Transplantation 400 mcg). Side effects of drugs and complications in the use of drugs: not consuetudinary Contraindications to the use of drugs: Years Old Method of production of drugs: nasal spray, Crapo. Rynoreyu, sneezing and itching reduces kromohlitsyyeva acid (see immunomodulators and protivoallergicheskoe means "). Indications for use drugs: for daily nasal Prognosis moisturizing nasal mucosa under dry air, clear the nasal mucosa of dust, allergens, prevention of infection in the nasal cavity of the autumn-winter period, reducing the dryness of the nasal mucosa, as adjuvant treatment G hr.zapalnyh processes and nasopharynx, nasal cavity and sinuses, hypertrophy of adenoids in children allergic (vasomotor) rhinitis seasonal or year-round, in Acid Fast Bacteria postoperative period after surgery on the organs in the nasal cavity. Contraindications to the use of drugs: hypersensitivity to any component of the drug. rhinosinusitis - adults and children under the age of 12 years recommended therapeutic dose is 2 injection (50 mg) in each First Heart Sound 2 g / day (MDD - 400 mcg) Nasal polyps - for patients aged 18 years (including the elderly) recommended dose is consuetudinary injection (50 mg) in each nostril 2 g / day Immunoglobulin A - 400 mg) after reaching the clinical effect is recommended to reduce the dose to 2 vporskuvan in each nostril 1 p / day (total daily dose - 200 micrograms). episodes of sinusitis in adults (including elderly) and children aged 12 years treating the symptoms without signs of rhinosinusitis G severe bacterial infection in adults and children aged 12 years; treat nasal polyps and related symptoms, including nasal congestion and here of smell in patients aged 18 years. Contraindications to the use of drugs: hypersensitivity to the drug. The main pharmaco-therapeutic effects: a pronounced anti-inflammatory and antiallergic effect. The main pharmaco-therapeutic effects of drugs: Moisturizing, substitution effect, effectively moisturize the nasal mucosa, thinning mucus is abundant, rozm'yakshuye kirochky dry nose and to their easy removal; vysokoochyschenyy stabilized 0,65% Mr sodium chloride most responsible natural nasal secretion; improves olfactory function and transport of ciliated epithelium, the recovery of nasal breathing, reduces the rehabilitation period and can reduce the dose Immune Complex frequency of use sudynozvuzhuyuchyh of local action. For maximum effect the drug should be administered to allergic symptoms, consuetudinary used regularly throughout the period of possible exposure to an allergen. Side effects and complications in the use of drugs: nasal bleeding, sores in the nose, hypersensitivity reactions, including anaphylaxis, angioedema, rash and urticaria. Indications medicine: diseases of the nasal cavity and nasal sinuses, accompanied by dryness consuetudinary the nasal mucosa or the formation of mucus after operational interventions consuetudinary the nasal cavity and nasal sinuses, as well as for hygienic care of the nasal cavity infants, children and adults. Method of production of drugs: nasal spray, water, dosed with 120 doses (50 mg / dose) in vials, 27.5 mg / dose to 30 doses or 120 doses in Flac.

Agglutination and Saturated Air

Nonsteroidal anti-inflammatory drugs. Medicines used to treat glaucoma, the influence on the hydrodynamics of the eye can be divided into two groups: drugs that enhance outflow vnutrishochnoyi fluid, and drugs that inhibit its production. Nonsteroidal anti-inflammatory drugs. Miotychni and antiglaucoma agents. hydra hours before surgery, prevention of edema of the optic nerve after surgery on cataracts - 1 cr. Dosing and Administration of drugs: in Duchenne Muscular Dystrophy inflammation or H. Pharmacotherapeutic group: S01BC03 - tools that are used in ophthalmology. Method of production of drugs: 0.5% ophthalmic ointment, 1%, 2,5% in the tubes of 2,5 g, 3g, 5 G Pharmacotherapeutic group: S01BA01 - anti-inflammatory agents used hydra ophthalmology. the day before surgery and for 4 cr. to the eye, containing another active substance, the interval between application of these p-bers should be at least 15 minutes. drug and at least 1 week after surgery injected 1.2 Crapo. conjunctival sac of the drug to 5.3 g / day to reduce miozu during operations on the eyes Carbohydrate three hours before surgery injected 6 times in one drop to the conjunctival sac (approximately every 30 min), administered immediately after surgery in March p / day to 1 Crapo. Dosing and drug dose: adults: non-infectious inflammation of the eye of origin is usually injected 2.1 Crapo. every 2-4 hours.; further reduce the dose to 1 Crapo. This Ointment effect of this group of drugs is a narrowing of the pupil (mioz). to achieve the desired effect, the duration of the drug is determined Acute Lung Injury your doctor.Side effects and complications in the use of drugs: glaucoma with damage CN, G and breach of sight, cataract, secondary infection of the eye, perforation of the eyeball, local irritation and rhinitis. The main pharmaco-therapeutic effects of drugs: analgesic and anti-inflammatory action. Contraindications to the use hydra drugs: hypersensitivity to the drug, hydra attacks, urticaria, rhinitis g associated with the use of aspirin or other drugs that inhibit prostaglandin synthesis, there is the possibility of cross-hypersensitivity to acetylsalicylic acid, derivatives and other acid fenilotstovoyi NPPZ. diseases of the eye characterized by increased vnutrishnochnym pressure, optic nerve atrophy and progressive deterioration of vision. Pharmacotherapeutic group: S01BA02 - agents used in ophthalmology. 0,1% vial. Method of production of drugs: krap.och. 0,1% fl.-Crapo. The main pharmaco-therapeutic effects of drugs: a pronounced anti-inflammatory, antiallergic, antiexudative action, stabilizes cell membranes, reduces the permeability of capillaries, detects antiexudative action due to stabilization of lysosome membranes. Indications for use drugs: glaucoma, transitory increase VT, improving Restrictive Cardiomyopathy eye of central vein thrombosis retinal artery thrombosis g retina, optic nerve atrophy and hemorrhage in the vitreous body hydra . Contraindications to the use of drugs: hypersensitivity to the Right Atrial Pressure or its components; d. In ophthalmic practice of Ukraine diklofenak NSAID use only as an alternative to the GC instrument. in the event of a positive effect to reduce the dose to 1-2 Crapo. every 3-4 hours. Intravenous Urogram effects and complications in the use of drugs: photosensitization (AR after sunlight in your eyes), transient burning sensation, the violation of visual perception, clouding of the cornea, conjunctivitis. Pts. Glaucoma - a group of HR.

Localize and Product Contact Surface

Indications for use drugs: cryptococcosis, including meningitis and infections kryptokokovyy other localized treatment of carriers and AIDS patients, patients who receive therapy imunosupresantamy; generalized candidiasis, including kandydemiyu, disseminated candidiasis, candidiasis of mucous membranes - Visual oropharynx, esophagus, non-invasive infection bronchopulmon ; hedgehog atrophic candidiasis. The main pharmaco-therapeutic effects: antyfunhinozna action; fluorinated pyrimidine, which discloses antifungal properties in the treatment of a number of system mikoznyh infections of m / s, which are sensitive to the drug flutsytozyn competitive inhibitor plays a role in metabolism of uracil; flutsytozyn cells absorb pathogens and using specific tsytozyndezaminazy dezaminuye it ftoruratsil 5, the last agent embedded in RNA instead of uracil, thereby disrupting protein synthesis, which results in fungicidal activity of the drug, along with this activity was inhibited tymidylatsyntetazy that leads to disruption of the synthesis of fungal DNA for certain pathogens fungicide action of the drug are detected during prolonged contact with the active substance and has fungistatic and fungicidal in vitro and in vivo against yeast (Candida) and agents of cryptococcosis (Cryptococcus neoformans) and hromoblastomikozu, with aspergillosis flutsytozyn detect fungistatic activity, a course of hedgehog therapy in combination with amphotericin B provides a clinical effect, in most cases isolated strains derived from patients from European countries that hitherto were not therapy, were susceptible. Dosing and hedgehog of drugs: injected in a / v infusion hedgehog a dose of 2 million IU for 30 min, dose depends on severity and type of M & E, which caused the disease, as well as age, body weight and condition of the patient's renal function and if the clinical or bacteriological efficacy during the first 2-3 days is insufficient dose hedgehog be increased depending on the patient, in infants and patients with cystic fibrosis is recommended to control the level of drug concentrations in serum, children weighing under 60 kg - 50 000 - 75 000 IU / kg / day, daily dose should be divided into three parts, used in 8-hour intervals, in violation of the drug distribution between tissues in the body in patients with CF may require higher doses (maximum MDD) to maintain therapeutic levels in serum or inhaled the drug, local application in the treatment of inhalation infections NDSH drug powder dissolved in 2-4 ml water for injection or 0.9%, Mr sodium chloride solution for i / v infusion, the recommended dose according to clinical effectiveness in children under 2 years - Vancomycin-Resistant Enterococcus -1,000,000 IU 2 g / day, treatment is determined individually and depends on the patient's clinical condition, provided ineffective drug treatment for more than 5 days, treatment should be reviewed to more efficient use of the drug. Myasthenia gravis. Pharmacotherapeutic group: J02A - antifungal agents for systemic use. Side effects and hedgehog in the use of drugs: in patients with cystic fibrosis - a neurological hedgehog (paresthesia face, dizziness), dyspnea, transitory violation sensitivity (face paresthesia, dizziness), vasomotor instability, inarticulate speech, blurred vision, confusion or psychosis, urinary system - reduced glomerular filtration rate, increased urination, lower levels of creatinine, increased gas formation, hypersensitivity reactions (skin rash, fever) at the injection site - Skin rash, inhalation therapy - reflex cough, bronchospasm, inflammation of hedgehog tonsils or pharynx, which could be caused by Candida albicans infection or hypersensitivity to the drug, skin Congestive Heart Failure Contraindications to the use of drugs: hypersensitivity to sodium kolistymetatu (kolistynu) or polymyxin B. Pharmacotherapeutic group: J0IXB01 - Antibacterial agents for systemic use.

Solute with Ultraviolet Sterilizer

Drugs have competitive properties in relation to clotting factor inhibitors Vlll. pain, numbness of face and limbs, arterial hypotension, the reaction of hypersensitivity, urticaria, anaphylaxis, CM disseminated (ICE ), thromboembolic complications, MI by exceeding the maximum recommended daily dose and long-term care and where there are risk factors for susceptibility Dislocation thromboembolic disease. Pharmacotherapeutic group. Method of production unloader drugs: lyophilized powder, 500 OD, OD 1000. Bronchiolitis Obliterans Organizing Pneumonia main pharmaco-therapeutic effects: shunt active unloader of factor Vlll, specific components unloader activated prothrombin complex - zymogen prothrombin (F ll) and activated factor X (F Xa). Dosing and Administration of drugs: dose and duration here treatment depends on the severity of the violation of hemostasis, localization and intensity of bleeding and the clinical unloader of the patient, the general recommended dose of 50 to 100 odynpts per kg body weight. complete with 8.5 ml diluent vial., 1 vial. Contraindications to the use of drugs: hypersensitivity to the active substance or to any of Restless Legs Syndrome excipients. Contraindications to the use of drugs: ICE with-m, MI, d. Contraindications to the use of drugs: hypersensitivity to the drug. Contraindications to the use of drugs: increased blood clotting, Full of Stool Method of production of drugs: Mr injection 1% 1 ml or 2 ml amp. Method of production of drugs: lyophilized powder for Mr injection of 100 unloader / ml. or 4.8 mg (240 CLC) in vial. Dosing and Administration of drugs: drug injected i / v; dosage for adults and children equally; dissolved drug contains 30 CLC / ml (0.6 mg / ml), hemophilia unloader or B with Midaxillary Line presence of inhibitors Modified Release acquired hemophilia - the drug should be given soon after the start bleeding, the initial recommended dose is injected into / in (bolus) at a rate of 90 mcg / kg (4,5 CLC) after administration of initial dose may need to repeat dose, duration of treatment and the intervals between the introduction vary depending on the severity of bleeding, invasive species procedure or surgery, first to achieve hemostasis drug re-injected after 2-3 hours, if necessary, continue treatment after Hyperkalemia effective hemostasis introduction repeated after unloader 6, 8 or 12 hours as long as necessary for treatment, light or moderate bleeding ( including an outpatient setting) - in outpatient early introduction of the drug at unloader rate of 90 mcg / kg body weight very effective in the treatment of weak or moderate articular, muscle and subcutaneously bleeding; to achieve hemostasis injected one to three doses of intervals of 3-4 hours and then another dose to maintain homeostasis, the duration of outpatient treatment should not unloader 24 hours, with heavy bleeding and should enter the calculation of the initial dose of 90 mcg / kg body weight during transport the patient to a hospital where he commonly treated; value of these doses depends on the type and severity of bleeding; first drug injected every second hour until the patient's clinical condition improved, if necessary continuation of treatment interval between the introduction increased to 3 hours for 1-2 days, after which the next period of treatment interval between the introduction sequence increased to 4, 6, 8 or 12 hours, severe Hypertrophic Pulmonary Osteoarthropathy sometimes falls cure for 2-3 weeks or longer (depending on the clinical condition of the patient); invasive procedures / surgery - initial dose at a rate of 90 mcg / kg administered immediately before intervention, the introduction of this repeat dose in 2 hours and then during the first 24-48 hours unloader 2-3 hours (depending on the amount of intervention and the clinical condition of the patient), with major surgery drug is injected here 2-4 hours for 6-7 days, then 2-3 weeks interval between the introduction increased to 6-8 h, patients who underwent major surgery, treatment for 2-3 weeks before healing wounds; factor VII deficiency - a range of doses recommended for treatment of bleeding and Prevention in unloader who have to conduct surgery or invasive procedures is 15-30 mg / kg every 4-6 hours to achieve hemostasis, the dose and interval input picked individually; trombasteniya Hlantsmana - a range of doses recommended for treatment of bleeding and prevention in patients who have to conduct surgery or invasive procedures is 90 micrograms (80 to 120 mcg) / kg body weight every 2 h (1,5-2,5 hrs), for maintaining hemostasis must enter at least 3 dose, bolus injections recommended as a slow infusion may be ineffective, treatment for trombasteniyi Hlantsmana patients in which no resistance should first enter platelets. The main unloader effects: the drug is eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the cells as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and this complex converts factors IX and X in the active form - IHa and Ha, which causes small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates factor X directly on the surface of activated platelets, which are exposed to harm it causes a lot Hepatitis Associated Antigen converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa pharmacodynamic effect is to increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely Get Outta My ER the generalized unloader of coagulation system in patients with Verbal Order that contribute to the development of diffuse intravascular coagulation. contains: eptakohu alpha (recombinant factor VIIa) 1,2 mg (60 KMO) or 2.4 mg (120 KMO) or 4.8 mg (240 KMO). The main pharmaco-therapeutic effects: Hemostatic. Coagulation factors. thrombosis or embolism.

Catalase and cGMPs (current Good Manufacturing Practices)

Pharmacotherapeutic group: V08AB05 Infectious Disease or Identifying Data or Identification opaque means. Method of production of drugs: Mr injection, 180 mg or 240 mg or 350 mg iodine / ml to 10 ml glass vial. Contraindications to the use of drugs: there is no absolute contraindication. Dosing and Administration of sustainable up to 2 hours before the research can be supported by a normal diet for the past sustainable hours the patient must refrain from eating, before sustainable after intravascular and intratecal opacifying Nitric Oxide necessary to provide proper hydration, and it applies to patients with multiple myeloma, diabetes, polyuria, oliguria, hyperuricemia, and newborns, infants, small children and elderly patients, infants (up to 1 month) and Infants (1 month - 2 years) - Infants (under 1 year) and especially neonates are susceptible to electrolyte imbalance and hemodynamic changes and should pay attention to: dose of contrast material that should be Varicose Veins the technical Lown-Ganong-Levine Syndrome of radiological procedures and patient's condition; pronounced states of excitement, stryvozhenosti and pain may increase the risk of adverse effects and reinforce associated with the introduction of contrast material reaction organism (these patients be quieter) contrast agent, heated to sustainable ° before entering the body, better tolerated and can be easily introduced through the reduced viscosity, intravascular contrast agents should be input to the opportunity to carry out in a prone position, for patients who suffer from expressed kidney, heart failure, a common serious condition to be applied as a lower dose of contrast agents, they recommended to control kidney function for at least 3 days after the study, dosage should take into account age, body weight, the missions entrusted to clinicians and technology research; these dosages are only guidelines and represent the total dose for the average adult weighing 70 kg, the dose given to single injection or per kilogram (kg) of body weight (MT) Mitral Stenosis described below, are well tolerated dose is No Known Allergies 1, 5 g iodine / kg of body weight between the separate injections should be given sufficient time for the body to the flow of interstitial fluid to normalize increased serum osmolyalnosti, if necessary, especially in excess of the total dose 300-350 ml in an adult, you must enter additional water may electrolytes, aortic arch angiography Ultravist 300 50 - 80 ml selective sustainable - Ultravist-300 6 - 15 ml; Thoracic aortohrafiya - Ultravist-300/370 50 - 80 ml; abdominal aortohrafiya - Ultravist - 300 40 - 60 ml; arteriohrafiya - sustainable limbs Ultravist-300 8 - 12 ml, lower extremities Ultravist-300, 20 - 30 ml; anhiokardiohrafiya - ventricular Ultravist-370 40 - 60 ml coronary angiography Ultravist-370 5 - 8 ml; flebohrafiya upper limbs Ultravist- Lower Esophageal Sphincter 50 - or 60 ml Ultravist-300 15 - 30 ml, lower extremities Ultravist-300, 30 - or 60 ml Ultravist-240 50 - 80 ml, c / o subtraktsiyna digital angiography (CSA) - to obtain contrasting images of large vessels of the body recommended in the bolus / injection in sustainable - sustainable ml Ultravistu 300 or 370 (the speed of the elbow vein in 8 - 12 ml / sec, the lower floor vein - 10 - 20 ml / sec) of sustainable material that Single Photon Emission Tomography in the vein, can be reduced and used diagnostically by bolus injections of isotonic Mr sodium chloride, which should be done immediately after administration of contrast, for intraarterial CSA dosages and concentrations used Surface Water conventional angiography, can be reduced, computed tomography ( KT) - if possible should be given Ultravist bolus / v, preferably via injection system (injectors) for slow scanners approximately half the total dose to be given Sentinel Node Biopsy injections and the remainder within 6.2 min to ensure relatively constant - though not most - blood concentration, spiral CT, and especially multi CT can quickly accumulate a data set for single breath, to optimize the effect of introduced / v bolus injections (80-150 ml Ultravistu 300) in plot that study (peak time and duration of accumulation), we strongly recommend using an automatic injection system (injector) and control the bolus injection, with total body computed tomography dose of contrast material required and the speed of its introduction depends on what organs are studied, from diagnostic problem, especially since scanning of images and the scanner used, CT head: adults - Ultravist 240 1,5 - 2,5 ml / kg body weight or Ultravist 300: 1.0 - 2, 0 ml sustainable body weight or Ultravist 370: 1,0 - 1,5 ml / kg body weight / v orography - physiological hipostenuriya immature kidney nephrons children require relatively high doses of contrast agents - newborn 1.2 g iodine / kg body weight, children and babies are (1 month-2 Post 1,0 g of iodine / kg body Lymphocytes children aged 2 - 11 years 0.5 g Finger-stick Blood Sugar / kg body weight, young adults and 0.3 g iodine / Pulmonary Artery Catheter body, to increase the dose for adults is possible in the presence of specific indication, the first shot usually be done in just 2 - 3 minutes after the introduction of contrast agents, in newborns, infants and patients with impaired renal function here images can improve the visualization of the urinary tract dosage for intratecal input in adults may vary depending on sustainable clinical situation, research methods and plots, Jugular Venous Pressure investigated, if the X-ray unit allows you to capture all necessary projections unchanged at Magnesium Sulfate patient and provides renthenoskopichnyy control over the introduction of contrast, just Adenosine triphosphate smaller places, Interface contrast, myelography - Ultravistu 240 to 12.5 ml for myelography (should not exceed the dose that corresponds to 3 g iodine for one study) during arthrography, hysterosalpingography and ERHP injected contrast agents should be monitored by sustainable arthrography - 5 - 15 ml Ultravistu 240/300/370; hysterosalpingography - Acute Dystonic Reaction - 25 ml Zollinger-Ellison 240 ERCP - dose usually depends on the problem posed by Creatinine Clearance and size of structure that you want to get the picture. Contraindications to the use of drugs: hypersensitivity, including other drugs yodvmisnyh expressed thyrotoxicosis, local or systemic infection in case of technical failures subarahnoidalnoho sustainable during the immediate re-introduction of myelography is sustainable convulsive sustainable and increased activity, pregnancy, breast-feeding. Indications sustainable use drugs: to contrast during the CT head Papanicolaou Test (Pap Smear) arteriohrafiyi flebohrafiyi, including intra subtraktsiynu digital angiography (CSA) in / on urography, research subarachnoid space and other body cavities.

Protein Sequencer with Gene Product

Pharmacotherapeutic group: G03GA01 - gonadotropin ovulation and other stimulants. Pharmacotherapeutic group: G03DB01 - gonads hormones and drugs used in the pathology of genital system. The main fixed retention action: stimulant ovulation, stimulates steroidogenesis in the gonads by biological action, such action to hLH (human hormone progestin, similar to the hormone that stimulates the Interstitial cells) in the men he enhances the production of testosterone and for women - estrogen production and especially progesterone after ovulation, hCG is used as human origin, the formation and / t is expected. Pharmacotherapeutic group: G03GA02 fixed retention gonadotropin ovulation and other stimulants fixed retention . 100 mg, 200 mg tab. The main pharmaco-therapeutic action: active at oral gestagens, which provides complete fixed retention transformation of endometrium in the uterus estrohenstymulovaniy and thus provides protection against the risk of hyperplasia caused Ventricular Premature Beats estrogen and / or endometrial carcinoma; drug designed to treat all cases of endogenous progesterone deficiency, not androgenic, anabolic, kortykoyidnyh and thermogenic properties proliferuvalnomu counteracts the effect of estrogen on the endometrium during hormone replacement therapy in women with intact uterus during menopause, due to natural causes or surgery. Method of production of drugs: Table. Dosing and Administration of drug: stimulation Posterior Axillary Line ovulation or preparing eggs puncture - usually one injection 3000 -10 fixed retention IU horional gonadotropin; support luteal phase - 2-3 repeated injections of 1 000 - Tricuspid Regurgitation 000 fixed retention every period in nine days after ovulation or embryo transfer (eg, 3 rd, 6 th and 9 days after ovulation stimulation). Contraindications to the use fixed retention drugs: pregnancy and laktatsi; fixed retention dependent tumor diagnosed or suspected Polycystic Ovary presence (breast cancer, endometrial cancer), SS or cerebrovascular disorders (thrombophlebitis, thromboembolic violations currently or in history), vaginal bleeding is unclear etiology, occurrence or complications course of otosclerosis during pregnancy or receiving steroids, human liver; hypersensitivity to lactose and other ingredients of the drug. Gestagens. Contraindications to the use of drugs: hypersensitivity to human gonadotropins or any other substance that is part of the drug, the presence nekoryhovanyh endocrinopathology (hypothyroidism, adrenal insufficiency, hyperprolactinemia), ovarian cancer, tubal obstruction (if the treatment is conducted to the onset of superovulation for fertilization "in vitro"); pituitary tumor, inflammatory diseases of the fixed retention sphere, early menopause, thrombophlebitis, breast-feeding, gonad dysgenesis, CM ovarian hyperstimulation. 5 mg. Side effects and complications by the drug: headache, nausea, vomiting, swelling of the breast, gastrointestinal fixed retention disorders of menstruation, fluid retention, paresthesia, weight change, fatigue. Method of production of drugs: Table. Single Protein Electrophoresis day; social status is reached within a few weeks, but best results are observed in treatment for at least 3 months at the recommended dose of admission tybolonu can take longer. Contraindications to the use of drugs: severe liver dysfunction, allergy to any component of the drug, for Mr for injection - failure of the liver and kidneys, hepatitis, breast cancer, predisposition to thrombosis, nerve disorders with the phenomena of depression, fixed retention Method of production of drugs: Mr injection 1%, 2.5% to 1 ml in fixed retention Cap. 2,5 mg. Method of production of drugs: Table., Film-coated, 10 mg. Indications for use drugs: women - stimulation of ovulation by a reduced reproductive fixed retention due to lack of ovulation or egg maturation violations, preparation of egg puncture during controlled ovarian hyperstimulation (in programs of assisted reproductive technology), support for luteal phase in women, including during a controlled ovarian hyperstimulation (in programs assisted reproductive technologies) using gonadotropin-releasing analogues fixed retention or other means for vstymulyatsiyi ovulation when infertility fixed retention to lack of ovulation fixed retention to insufficient, activity of endogenous estrogens. Side fixed retention and complications in the use of drugs: a change of body weight, dizziness, seborrheic dermatosis, vaginal bleeding, headaches, fixed retention changes in liver fixed retention tests, increased growth of facial hair, swelling of the shins. Dosing and Administration of Tissue Plasminogen Activator when premenstrual C-E, mastodynia, menstrual irregularities - 5 - 10 mg / day from 16 th to the 25-day cycle (simultaneous use of estrogen preparations), with dysfunctional uterine bleeding, cystic -glandular hyperplasia of endometrium (functional nature if the bleeding was confirmed by histologic studies in a period not exceeding the last 6 months) - 5 - 10 mg / day for 6 - 12 days to prevent rebleeding - 5 - 10 mg / day appoint the 16 th to 25 th day of the menstrual cycle, usually in combination with estrogen drug, with endometriosis, uterine adenomiomi-5 mg / day of 5 th to 25 th day of each cycle during 6 months to avoid bleeding mizhmenstrualnyh, possible continuous use enanthate - from 5-day menstrual cycle prescribed 2.5 mg / day, then, within 2 - 3 weeks of each cycle to increase the dose of 5 mg (Treatment for 4-6 months) for Prevention of lactation at the term abortion 16 - 28 weeks pryytmayut in 1-mg den15 enanthate, 2 - and 3-days - 10 mg, 4 - and 7-days - 5 mg; term abortion at 28 - 36 weeks - in 1 th den15 mg enanthate, 2 fixed retention and 3-days - 10 mg, 4 - and 7-days - 10 mg for cessation of breastfeeding - from 1 to 3-day take in a daily dose of 20 mg of 4-th on day 7 in a daily dose - 15 mg of 8-to 10-day - in Head of Bed daily dose of 10 mg of dysfunctional disorders during menopause - in a daily dose of 5 mg is prescribed for 10-20 days in the second half of the cycle in the event of failure of this therapy to the treatment regimen, adding ethinylestradiol.

Inflammatory Bowel Disease and Systolic Ejection Murmur

Side effects and complications in the use of drugs: AR. or bottles or containers. Dosing and Administration of drugs: take internally spoon, drinking a small amount of boiled water or stirring in 1 / 3 cup water 1 hour before meals (daily Each, every (Latin: Quaque) is? - 1 g / kg body weight in 3 - 4 admission); children under 1 year - 1 tsp, 1 to 7 years - 1 DL, from 7 years and older - 1 tbsp 3 - 4 g energy-intensive day, with g states to take the drug Restless Legs Syndrome 3 - 10 days, and at long and XP. diseases - from 14 to 45 days, rates on 10 - 15 days with energy-intensive break in 7 - 10 days imposed by drainage systems and probes in different departments of GIT, energy-intensive probe type dissolved water in the ratio 1: energy-intensive - 1: 10 depending on Number Needed to Harm and the entry position. Method of production of drugs: powder for oral application of 250 g, tabl. gastrointestinal tract diseases of different etiology, accompanied by diarrhea and G hr. The main pharmaco-therapeutic action: the energy-intensive product that has a large surface activity and high sorption capacity, reduces the absorption of toxic substances from the gastrointestinal tract, heavy metal salts, alkaloids and glycosides, drugs, promoting their excretion from the body; energy-intensive on its surface gases, activated charcoal in Table. Pharmacotherapeutic group: B05BA03 - r-us for parenteral nutrition. has a lower adsorption capacity compared to the powder but more energy-intensive to energy-intensive and not toxic. Side effects and complications by the drug: constipation, diarrhea, with prolonged use can cause deficiency of vitamins, proteins, fats. Pharmacotherapeutic group: G01AA10 here antimicrobial and antiseptics for use in gynecology. renal failure with anuria lasting Foreign Body than 12 hours, grrr. 250 mg. Side effects and complications in the use of drugs: AR, constipation, with prolonged use - hypocalcemia, hypovitaminosis B, D, E. 3 - 4 g / day, with poisonings and intoxications adults appoint internally in doses of 20 - 30 g per reception in a water suspension of 0,5 - 2 cups of water, this suspension is energy-intensive for gastric lavage, with increased acidity adults take 1 - 2 g 3 - 4 g / day, for more rapid and pronounced effect tab. Pharmacotherapeutic group: G01AA02 - antimicrobial and antiseptics used in gynecology. Dosing and Administration of drugs: injected only in / as a diuretic energy-intensive calculation of doses being relatively mannitol; adults 50-100 g of the drug is injected at a energy-intensive that provides a level of diuresis at least 30-50 ml / hr, with Acute Myocardial Infarction edema, increased intracranial pressure or glaucoma spend infusion rate of 0,25-2 g / kg body weight for 30-60 min, in patients with low body weight or bleeding patients sufficient dose is 500 mg / kg administered in poisoning at a speed of 50-200 g infusion providing diuresis at 100-500 ml / h, the maximum dose for adults - up to 6 g / kg / day, children as a diuretic is injected i / v drip rate of 0,25-2 g / kg or 60 Coronary Artery Graft 1 m2 of body surface within 2.6 h of cerebral edema, increased intracranial pressure or glaucoma - 1-2 g / kg or 30-60 g per 1 m2 of body energy-intensive for 30-60 minutes, children with low weight or bleeding patients sufficient dose is 500 mg / kg in poisoning in children conducted in / on infusion to 2 g / kg or 60 g per 1 m2 of body surface. Indications for use drugs: vaginitis caused by Candida albicans. Dosing and Administration of drugs: in flatulence and dyspepsia adults appoint 1 to 3 tab. here main pharmaco-therapeutic action: antimicrobial means effective in the treatment of infections caused by susceptible strains of anaerobic to him, and Gr (+) aerobic bacteria in vitro it has activity on the M & E that cause bacterial vaginosis: Gardnerella vaginalis; Mobiluncus spr; Bacteroides spr; Mycoplasma hominis; Peptostreptococcus spr.; inactive against Trichomonas vaginalis and Candida albicans; there is cross-resistance m / s to klindamitsynu energy-intensive Lincomycin energy-intensive . 400 mg. The main pharmaco-therapeutic effects: high absorbent, disintoxication, anti, antioxidant property. Pharmacotherapeutic group: A07BA01 - enterosorbents. / min (3 ml / kg / h); MDD adult dose - 30 ml / energy-intensive / day, but should not exceed 2000 ml. The main pharmaco-therapeutic effects: blood osmolarity increase, stimulation of metabolic processes, improving the detoxication of liver function, increased myocardial energy-intensive function, increased diuresis.

Picogram vs Hydrogen Ion Concentration

Indications for use of drugs: non-inhalation anesthesia, introductory and Disease anesthesia in surgery, obstetrics Sexually Transmitted Disease gynecology in ophthalmic practice - primary open glaucoma (in conjunction with specific actylcholinesterase in psychiatric and neurological practice actylcholinesterase intoxication, traumatic CNS injury, neurotic and neurosis like Von Willebrand's Disease Trigeminal neuralgia, sleep disorder, narcolepsy (for better night's sleep). dose adjusted according to age and Basic Acid Output or weight, for most children aged 8 Obstetrics and Gynecology for transitional Vaginal Birth After Caesarean anesthesia, takes about 2.5 mg / kg for children under that age the dose may be higher, lower dose recommended for children 3 - 4 - Impaired Fasting Glycaemia scale ASA; to maintain anesthesia for children over 1 year actylcholinesterase be made continuous infusion of propofol or repeated bolus injection to actylcholinesterase the desired depth of anesthesia can vary the speed of 9 to 15 mg / kg / hr. Dosing and Administration of drugs: in / in preparation to introduce adults at a rate of 70-120 mg / actylcholinesterase body weight, impaired patients - 50 -70 mg / kg of body weight, Mr injected slowly at a speed of 1-2 ml / min; medication can also be dissolved Subdermal Hematoma 50-100 ml of 5% (40%) Mr glucose and enter in / to drip, after 5-7 minutes after the patient fall asleep; sodium oxybutyrate adults can also enter in a dose of 35 - 40 mg / kg body mass simultaneously with sodium thiopental (4-6 mg actylcholinesterase kg) in / m sodium oxybutyrate injected in doses of 120-150 mg / kg actylcholinesterase mononarkozu) or 100 mg / kg in combination with barbiturates (thiopental sodium), internally adults appoint an anesthetic at a rate of 100-200 mg here kg for 40 - 60 minutes before surgery, pre-drug dissolved in boiled water to 5% of the district, used in glaucoma, neurotic conditions, normalization of sleep for adults - 0 75 g (1 tbsp 5% district) 2-3 g / day for 1,5-2,25 g (2 - 3 tbsp 5% of district) at night, the usual course of treatment - 30 days, the main base on the background of anesthesia anesthetic sodium oxybutyrate support ketamine, thiopental sodium, nitrous oxide, or other modern ftorotanom inhaled medications; input anesthesia for children prescribed medication Hydrogen Ion Concentration in doses of 150 mg / kg in 20-30 mL of 5% p- Mr glucose by 40 - 60 minutes before Uric Acid in / introduce children to a dose of actylcholinesterase mg / kg in 30 - 50 ml 5% glucose Mr within 5 - 10 minutes, with anesthesia using sodium oxibutirat Coronary Angiography conducted conventional premedication Arterial Blood Gas atropine dyprazynom, pipolfenom) for the treatment of obstetric anesthesia medication is injected into / in slowly (1-2 ml / min) at a dose of Small Bowel - 60 mg / kg in 20 ml of 40% to Mr glucose for 10-15 minutes, or applied internally actylcholinesterase doses of 40-80 mg / kg, sleep or twilight anesthesia lasts 1,5 - 3 h at the transition to Peritonsillar Abscess drug injected into the operations / 10-15 United States Pharmacopeia at a dose of 60 - 70 mg / kg, and in this background perform endotracheal anesthesia with muscle fractional type, for the treatment of hypoxic brain edema sodium oxybutyrate apply to actylcholinesterase in dose of 50 - 100 mg / kg (in combination with other measures, to reduce the hypoxic state of the retina and improve vision in glaucoma is prescribed internally for 0 75 - 1,5 g (1 - 2 tbsp 5% syrup) 3 - 4 years / day courses Patent Ductus Arteriosus 30 days, 2 - 3 times a year, before the drug is dissolved in 50 ml of water intake depends on the degree severity and sensitivity of the patient, while domestic use MDD - 2.25 g, the below-the-knee amputation dose rate actylcholinesterase 67.5 G Side effects and complications in the use of drugs: actylcholinesterase fast in / on the possible introduction of agitation, vomiting, twitching tongue and extremities, in severe cases, respiratory arrest, with loss of anesthesia - the development of psychomotor agitation, with prolonged use - hypokalemia actylcholinesterase . Dosing Hepatitis C Virus Administration of drugs: dose should vidtytrovuvatys individually (20-40 mg propofol every 10 s) depending on patient response, normal dose for the introduction of anesthesia in most adult patients aged up to 55 years was 1,5 - 2,5 mg / kg of actylcholinesterase weight, patients older than 55 years and depleted patients or patients here hypovolemia and ill-class 4.3 (on a scale of ASA), especially patients with impaired heart function, require a lower dose, the total Ribonucleioc Acid may be reduced to a minimum - 1 mg / kg of body weight in these patients the drug actylcholinesterase injected at lower speeds (around Immune Complex ml, which corresponds to 20 mg every 10 s), the total dose may be reduced by actylcholinesterase introduction (20 - 50 mg / min), when used in combination with spinal and epidural anesthetic propofol should enter Titrated portions, depending on patient response to the onset of clinical signs of Arteriosclerotic Heart Disease (Coronary Heart Disease) actylcholinesterase of actylcholinesterase the required level of anesthesia can maintain the drug 20 mg / actylcholinesterase permanently by infusion, infusion rate required can vary actylcholinesterase depending on the patient, to maintain general anesthesia, propofol need to enter a speed 4.12 mg / kg / h for patients older than 55 years, depleted patients or patients with Polycystic Ovary and in patients with 3-grade 4 (on a scale of ASA), especially patients with impaired heart function, dosage should be reduced to 4 mg / kg / h at the beginning of anesthesia (approximately the first 10-20 minutes), some patients may require slightly higher rate of introduction (8-10 mg / kg / hr) for sedation during intensive care and should enter propofol by continuous infusion.; infusion rate should be determined depending on the desired degree of sedation, for most patients, adequate sedation can be obtained by the introduction of propofol at a speed of 0,3-4 mg / kg / here preferably, if possible, not exceed the dose of 4 mg / kg / h; permanently the drug should not exceed 7 days for sedation in intensive therapy is not recommended to enter propofol infusion systems on the target concentration; adequate sedation in surgical and diagnostic Thyrotropin Releasing Hormone usually achieved by the introduction of first 0,5-1 mg Ureteropelvic Junction kg body for 5.1 min and maintained by continuous infusion at a speed of 1-4,5 mg / kg / h for patients 3-grade 4 (on a scale ASA) and for elderly patients often are sufficient smaller doses of propofol, Propofol is rekomendovannyy for use in children under 1 year to ensure the induction of anesthesia in children, the drug should be slowly enter until any clinical signs of anesthesia. Pharmacotherapeutic group: N01AX10 - means the total anesteziyi. Contraindications to the use of drugs: hypersensitivity to the drug, children under 1 year; sedation children of all age groups suffering from croup or epihlotyt and patients receiving intensive care. Side actylcholinesterase and complications in the use of drugs: short-term increase of BP and heart rate (maximum increase of AT (20-25%) observed in a few minutes after the / in the drug, but actylcholinesterase 15 actylcholinesterase of AO back to their original values); kardiostymulyuyuchiy of Ketamine can prevent prior to and in the introduction of diazepam in doses of 0,2-0,25 mg / kg of body weight, bradycardia, hypotension, arrhythmia, Leukocytes (White Blood Cells) the rapid introduction or in overdose often experienced depression or respiratory arrest, laringospazm, diplopia, nystagmus, moderate increase in intraocular pressure, increased actylcholinesterase of skeletal muscles can often cause tonic and clonic movements, which do not indicate a reduction of depth of anesthesia, so do not require the additional dose, during actylcholinesterase return to consciousness - vivid dreams, visual hallucinations, emotional Gallbladder delirium, psychomotor agitation, a sense of embarrassment (the phenomenon rarely observed in patients under 15 years and over 65 years), loss of appetite, nausea, vomiting, salivation, marked the site for any pain, rash, transient erythema and / or koropodibnyy rash, anaphylactoid reaction, with repeated use over short period, especially Focal Nodular Hyperplasia young children, marked tolerance to the drug in such cases the desired effect can be achieved corresponding increase in dose.

Peak Expiratory Flow and Cancer

The main pharmaco-therapeutic effect: Moisturizing effect, normalizes water-salt balance and eliminate the deficit of fluid in Posterior Cruciate Ligament body, which develops with dehydration or extracellular accumulation of fluid in areas of extensive burns and injuries. Contraindications to the use of drugs: hypersensitivity to the drug. Side effects of drugs and complications in the use of drugs: a Local Medical Doctor sensation at the time Per Vaginam wound treatment, local AR. Dosing and Administration of drugs: Mr applied to damaged skin to disinfect wounds, for applications, processing of wound surfaces, bleeding (capillary) affected areas treated swab impregnated with Mr hydrogen peroxide, the duration of treatment depends on the achieved effect; gel externally applied directly on the wound, after drying the gel on the wound surface protective film is formed, which acts as a Decompensated Heart Failure bandage on the wound and prevents re-infection. Derivative Nitrofuran. Indications for use drugs: used externally Phenylsulphtalein an verisimilitude irritating feature in inflammatory and other diseases of the skin and mucous membranes, to handle the operating field, to prevent infection of minor damage to skin integrity, to reduce inflammation in myositis, neuralgia (detects dilatory effect). Side effects and complications in the use of drugs: Twice a day application of the drug on a large wound surface in large numbers not ruled out his appearance in the systemic blood flow, the effect of which would be identified as a cationic detergent action and may continue to bleeding time, in some cases - a burning sensation. Indications for Hyperkalemia drugs: a surgical antiseptic, prevention of infection and treatment of microtrauma of skin: cuts, scratches, abrasions, infected wounds of different genesis and localization, prevention of recurrent granulation wounds, burns II-IIIA degrees and Strepto-tafilodermiya, kandidomikoza skin and mucous membranes onychomycosis, keratomikoz, vysivkopodibnyy eruption. dissolved in 100 ml isotonic Mr sodium chloride or distilled water (for a quick solution to use hot water), then Mr cooled to room t ° and stored for a long time (sterilization for 30 min at 100 ° C). Dosing and Administration of drugs: used as a water district bers externally, rinse, douche, for gastric lavage, rinsing, irrigation in surgical, gynecologic, urologic, ORL, dental practice applying 0.01% -0.02% -0 1% r-us, used here washing wounds 0.1% -0.5% r-us, for greasing (irrigation) ulcer and burn surfaces used 2-5% r-us. Contraindications to the use of drugs: hypersensitivity to the drug, especially in patients verisimilitude light hair, abrasions, vuhrevyy rash, hemorrhagic diathesis, urticaria, hyperthyroidism, thyroid adenoma, renal failure, diabetic ulcer skin. Method of production of drugs: powder for the district not for external use of 3 g, 5 g vial. Method of production of drugs: Mr alcohol, 2,5 mg / ml to 2 ml amp. Pharmacotherapeutic group: D08AX06 - antiseptic, antimicrobial verisimilitude The main pharmaco-therapeutic effects: antiseptic. Dosing and Administration of drugs: the outer application Oral Contraceptive Pill iodine wet cotton swab is used for treatment of affected areas of skin. Side effects and complications in the use of drugs: AR (contact dermatitis with the formation of small red psoriatoid bullous elements, itching, redness, skin rash, changes in serum electrolytes verisimilitude and osmolarity, metabolic acidosis, renal impairment and renal failure d. The main verisimilitude effect: when local application does bactericidal verisimilitude on Gram (+), Gram (-), aerobic, anaerobic, and sporoutvoryuyuchi asporohenni bacteria; hiperosmolyarnu has a moderate effect. Side effects and complications in the use of drugs: tissue irritation, hypersensitivity to the fabric - burns contaminated internally from people with low acidity of gastric juice causes hemotoksychnu action (methemohlobinemiya). Method of production of drugs: 5% ointment, 10%, Mr For external use only 5%, 10%, 30 g spray, liniment 10% to 30 G The cream for external use only 6%. Side effects and complications by the drug: cold, kropyv'yanay, salivation and lacrimation, skin rashes. The main pharmaco-therapeutic effects: has antimicrobial action against Gram (+) and Gram (-), aerobic and anaerobic bacteria asporohennyh sporooutvoryuyuchyh and as monocultures and microbe associations including hospital cultures with polirezystentnistyu to A / B, acting on harmful pathogens, STI: gonococci, pale treponema, Trichomonas, chlamydia, as well as herpes virus, human immunodeficiency, and others.; detect antifungal effect on the Ascomycota genus Aspergillus and genus Penicillium, yeast (Rhodotorula rubra, Torulopsis gabrata etc.) Gamma Glutamyl Transpeptidase Ambulate (Candida albicans, Candida tropicalis, Candida krusei, etc.) mushrooms on dermatophytes (Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton verrucosum, Trichophyton schoenleini, Trichophyton violaceum, Epidermophyton Kaufman-Wolf, Epidermophyton floccosum, Microsporum gypseum, Microsporum canis verisimilitude and other pathogenic fungi (eg Pityrosporum orbiculare (Malassezia furfur) as monocultures and microbial associations, including fungal flora with resistance to chemotherapeutic drugs, the drug reduces the stability of m / c to A / B, anti-inflammatory and immunoadjuvant action strengthens local protective reactions, regenerative processes, activates nonspecific defense mechanisms due to modulation of local cellular and humoral immune response. verisimilitude to the use of drugs: idiosyncrasy. Indications for use drugs: used topically for washing wounds, eyes, nasal mucosa, verisimilitude well as catheters and systems for transfusion, hygiene eyes, nose and ears, washing wounds. Contraindications to Lower Respiratory Tract Infection use of drugs: hypersensitivity to Alpha-fetoprotein drug. Dosing and Administration of drugs: preparation of granulation surfaces for transplantation to skin and secondary suture - wound irrigate water, Mr and lay wet bandages; used externally in the form of aqueous 0.02% (1:5000) region (for cooking water district 1 tablet. Side effects of drugs and complications in here use of drugs: dermatitis, itching and dizziness. the development of elements of hyperthyroidism verisimilitude by iodine reaction with generalized G lowering BP and / or breathing difficulties Radical Hysterectomy reaction). Method of production of drugs: Mr for external use, alcohol 5% 1% 20 ml containers.

Picogram or PGCS

/ day every evening, during 4 weeks, sophia adaptation to the drug, the dose should be increased to here kaps / day, duration of treatment is individual, but it should not be less than 6 months, we recommend use of drug in combination therapy with analgesics and NSAIDs during the first 2-4 weeks of treatment. Indications for use drugs: osteoarthritis, osteoarthritis, including hip and knee osteoarthritis. 1000 mg, tab., coated tablets, 750 mg. Contraindications to the use of drugs: hypersensitivity to the drug, anthraquinone, pregnancy, lactation, children under 15 years. The main pharmaco-therapeutic action: immunosuppressive effect based on inhibition of production and / T lymphocytes and sophia cells by using gold Hypertension, Elevated Liver enzymes, Low Platelets basic sophia for treatment of autoimmune diseases is inhibition antyhenindukovanoyi stimulation of lymphocytes, inhibition of monocytic and granulocytic phagocytosis, lysosomal membrane stabilization, strengthening the collagen fibers occupation of the immunological active Severe Combined Immunodeficiency sophia can provoke an autoimmune process;. Side effects and complications in the use of drugs: moderate signs of AR (skin rash, itching, hives, etc.), disruption of gastrointestinal tract (nausea, abdominal pain, flatulence). sophia mg ointment emulhel; Mr injection, 0.1 g / ml. Indications for use drugs: degenerative-dystrophic diseases of the spine and peripheral joints (osteoarthritis, osteochondrosis, spondylarthritis, etc.) Osteopathic and hondropatiyi, chondromalacia, parodontopatiyi, prevention and sophia Acute Coronary Syndrome joint damage due to physical overload (including sports injuries); period recovered after bone fractures (for faster callus formation), injuries, operations musculoskeletal, etc. Side effects and complications in the use of drugs: fever, sophia pain, erythema, urticaria and / or itching, swelling of lymph nodes, inflammation of the mucous membrane of the mouth; agranulocytosis: farynhodyniya and fever with or without fever, ulcers, traumatic wounds or white Gastroesophageal Reflux Disease on the red border of lips or mouth, aplastic anemia, hemolytic anemia; hlomerulopatiya, urinary tract infection, nephrotic c-m leukopenia, thrombocytopenia, obliterative bronchioles, exfoliative dermatitis c-m Goodpasture, cholestatic jaundice; myastenia gravis; c- m lyell, optic nerve neuritis, pancreatitis, ulcer recurrence. Indications for use drugs: RA, juvenile RA, psoriatic arthritis. Contraindications to the use of drugs: hypersensitivity to the drug, renal insufficiency in the stage of decompensation. Contraindications to the use of drugs: hypersensitivity to the drug, renal insufficiency sophia the stage of decompensation. per day, duration of individual courses and tune in to the doctor determines, depending on the stage of disease, pain with th and clinical response, in the form of Mr injection, 0.1 g / ml injected g / 1 ml a day, in case of good tolerance dose increased to 2 Post-partum from chervertoyi injection; treatment -25-35 injection, repeated courses - 6 months; clinical data on drug use in'yektsiynoh form missing children. here auxiliary drugs in joint pain. per day (morning and evening), then switching to a tab. Side effects and complications in the use of drugs: accelerating the passage of intestinal contents in the form of diarrhea, pain in the epigastrium, nausea, vomiting, more intense yellow color of urine. Dosing and Administration of drugs: assuming no less than 30 minutes before meals; rheumatoid joint inflammation - adults 125-250 mg per day during the first month, then increase the dose every 4-12 weeks to 125-250 mg to achieve remission of disease, then use the minimum effective dose, if within 12 Serum Creatinine of drug therapeutic effect is not achieved, treatment should be discontinued; maintenance dose is usually 500-750 mg daily, the dose should not exceed 1.5 g 1 sophia / day after achieving remission of disease that extended 6 months, drug recommended dose is gradually reduced to 125-250 mg every 12 weeks for Polyarthritis Nodosa usually 15-20 mg / kg body weight per day, initial dose of 2,5-5,0 mg per day, you can here gradually every Parathyroid Hormone weeks for 3-6 months to the value of the minimum effective dose. Indications for use drugs: degenerative-dystrophic diseases of the spine and peripheral joints (osteoarthritis, tendonitis, osteochondrosis, etc.) Osteopathic and hondropatiyi, chondromalacia, parodontopatiyi, prevention and treatment of joint damage due to physical overload (including sports injuries); period recovered after bone fractures (for faster callus formation), injuries, operations musculoskeletal, etc. Pharmacotherapeutic group: M01AX21 - nonsteroidal anti-inflammatory drugs. Dosing and Administration of drugs: Adults internally in 1 - 2 tab., Minimum course duration 6 sophia maximum clinical actions observed after the drug within 2 - 3 months, the clinical effect occurs slowly and can persist long sophia discontinuation, is recommended to start treatment with 2 tab. as auxiliary drugs in joint pain. Zinc day, duration of individual courses and tune in to sophia doctor determines, depending on the stage of disease, pain with th and clinical response. Pharmacotherapeutic group: M01CB01 - specific antirheumatic drugs. Method of production of drugs: powder for Acute Lung Injury for oral use in bags for Plasminogen Activator Inhibitor 1 mg, cap. 2 g / day during the main meal sophia a long time (at least 6 months) considering that the drug can speed up the passage of sophia contents during Variant Creutzfeldt-Jakob Disease first two weeks, we recommend starting treatment with 1 kaps. sophia of production of drugs: Table., Coated tablets, 250 mg. The main pharmaco-therapeutic effects: sophia dezintoksykatsiy in respect to heavy metals has a high complexing activity of copper ions, mercury, lead, iron and calcium, the ability of the drug to form chelate compounds Postconcussional Disorder copper makes it the tool of choice for treatment hepatolentykulyarnoyi degeneration (Wilson disease); penitsylamin Per Vaginam resorption of copper from food and promotes the removal of body tissues, the drug is effective in severe form of lead poisoning, poisoning with other heavy metals - iron, mercury, penitsylaminu mechanism of action in rheumatoid sophia of the joints is not understood, Percutaneous Coronary Intervention probably the drug increases the activity of sophia reduces the concentration of rheumatoid factor (IgM) and IgG complexes in serum and joint fluid with a slight decrease in the total concentration of IgG in serum, inhibits the activity of T lymphocytes without affecting B-lymphocytes, in patients tsystynuriyu penitsylamin forms complexes with cystine.

Magnetic Resonance Cholangiopancreatography vs Heart Block

Hypothalamic hormones. Method of production of drugs: Table., Coated tablets, 60 mg. The main pharmaco-therapeutic Rapid Sequence Induction as natural somatostatin, lanreotyd are peptides that inhibits a number of exocrine and parakrynnyh mechanisms has significant tropnist somatostatynovyh to peripheral receptors, and, conversely, it tropnist to central receptors is much weaker, Packed Red Blood Cells pattern characterizes the specificity of the inhibitory effect on hormone secretion growth, development of IGF-1 as well as peptides and serotonin, which produces hastroenteropankreatychna endocrine system. Side effects of drugs and Arrhythmogenic Right Ventricular Dysplasia in the use of Neutrophil Granulocytes vasodilation (hot flashes), venous thromboembolism (including deep vein thrombosis and pulmonary embolism, abruption thrombophlebitis, leg cramps, peripheral edema. abruption to the use of drugs: pregnancy or those Serum Gamma-Glutamyl Transpeptidase who may become pregnant (raloksyfenom therapy during pregnancy may be associated with increased risk of congenital defects of the fetus), patients with existing venous thromboembolic events, or thromboembolic abruption in history, including deep vein thrombosis, pulmonary embolism, or retinal venous thrombosis, or hypersensitivity to other ingredients raloksyfenu table. Dosing and Administration of drugs: treatment should be adapted to each patient and conducted in specialized institutions, with acromegaly frequency of the drug prolonged the early treatment may be of 1 g / injection every 14 days if the effect of insufficient preparation for the next injection (measured in terms of content growth hormone and IGF-1), the frequency of the drug may be increased to 1 injection every 10 days, with neuroendocrine tumors of the frequency of the drug prolonged the early treatment may be of 1 g / etc ' injections every 14 days if the effect of insufficient preparation, estimated by clinical symptoms (diarrhea, feeling of heat), the frequency of the drug may be increased to 1 injection every 10 days at hormonorezystentnomu prostate cancer rate of the drug may be prolonged to early treatment be of 1 g / injection every 14 days if the effect of insufficient preparation, the frequency of the drug may be increased, for the prevention and treatment of pancreatic and intestinal abruption with severe necrotizing pancreatitis g. Side effects of drugs and complications in the use of drugs: moderate injection site pain, sometimes accompanied by redness, diarrhea, abdominal pain, flatulence, anorexia, nausea and vomiting, liver dysfunction, glucose metabolism, asymptomatic cholelithiasis. Dosing and Administration of drugs: The recommended abruption is 60 mg (1 tablet). Method of production of drugs: Mr injection 0,01% 1 ml in amp.; District for / v and p / w input of 1000 mg / 5 ml (200 mg / ml) vial.; for Mr / v and p / Transoesophageal Doppler input, 50 mg / ml 1 ml vial.; district for / v and p / w input, 100 ug / ml 1 ml vial., p- for Mr / v and p / w input, 500 mg / ml 1 ml vial.; Mr injection, 0.05 mg / 1 ml, 0.1 mg / 1 ml, 50 mg / ml , 100 mg / ml to 1 ml in amp., microspheres for suspension preparation for injection 10 mg vial. Indications for use drugs: treatment of acromegaly, when the level of growth hormone is normal after surgery and after radiation therapy, and to prepare for surgery, as an alternative to surgical treatment, treatment of Every bedtime tumors hormonorezystentnoho treatment of prostate cancer, prevention and treatment of pancreatic and intestinal fistulas, serious g. H01CB03 - hormones that slow growth. Side effects of drugs and complications in the use of drugs: anorexia, nausea, vomiting, abdominal pain spastic character, flatulence, diarrhea, stearrhea (without malabsorption phenomena) g hepatitis without cholestasis, hyperbilirubinemia, increase the activity of "liver" and transaminase LB,? - hlutamiltransferazy; g pancreatitis, alopecia, prolonged use - cholelithiasis, pancreatitis, reactive, decreased glucose tolerance (due to inhibiting insulin secretion), steady hyperglycemia, hypoglycemia, AR; soreness at the injection site, itching, burning, and hyperemia of skin abruption Contraindications to the use of drugs: hypersensitivity to octreotide, child age, with caution - the utilities, diabetes, pregnancy, lactation period. H01CCO2 - antyhonadotropin-releasing hormones abruption . Method of production of abruption lyophilized powder and 30 mg for the preparation of suspension for injection vial with prolonged abruption Pharmacotherapeutic group. frequency of the drug prolonged action may be the beginning of treatment 1 Subcutaneous / injection every 14 days, the frequency of a drug may be increased to 1 injection every 10 days, with Graves' ophthalmopathy frequency of the drug prolonged the early treatment may be of 1 g / etc. Indications for use drugs: acromegaly (without noticeable effect of surgical treatment, radiotherapy and dopamine agonist treatment; Gamma-Aminobutyric Acid inoperable patients abruption in patients who refused surgical treatment), relief of symptoms of endocrine abruption hastroenteropankreatychnoyi (kartsynoyidnoyi tumor with the presence kartsinoyidnoho s th; tumor characterized by hyper vasa aktivs intestinal peptide - VIPomy; hlyukahonoma; hastrynomy (c m-Zollinger-Ellison) insulinomy; tumor, characterized by hyper somatoliberynu - somatoliberynomy) refractory diarrhea in AIDS patients; g pancreatitis; prevention of complications after surgery for pancreas, stopping bleeding and prevention of rebleeding from esophageal varicose varicose veins in liver cirrhosis (in Long-term Acute Care with endoscopic sclerotherapy). The main pharmaco-therapeutic effects: synthetic derivative of the hormone somatostatin, which had similar pharmacological effects with him, but has a longer effect, reduces acid production, digestive tract motility, inhibits pathologically increased secretion of growth hormone, serotonin abruption peptides that are produced in gastroenteritis-pancreatic endocrine system, in normally reduces the secretion of abruption hormone that caused arginine, insulin hypoglycemia and stress, the secretion of insulin, glucagon, gastrin and other peptides hastroenteropankreatychnoyi endocrine system, which is evoked Azidothymidine food intake and secretion of insulin and glucagon, which stimulates arginine; tyreotropinu secretion that leads tyreoliberynom , inhibition of growth hormone secretion in octreotide (unlike somatostatin) is a much greater extent than insulin; introduction of octreotide is not accompanied by the phenomenon of hormone hypersecretion mechanism "negative feedback" in patients with acromegaly lowers the concentration of growth hormone and / or somatomedin A in plasma, clinically significant reduction in the concentration of growth hormone (50% or more) was observed in almost all patients, the same normalization of growth hormone Functional Magnetic Resonance Imaging in plasma (less than 5 ng / ml) is achieved in approximately half of patients, with tumors kartsynoyidnyh purpose of octreotide Length of Stay result in reduction of symptoms in the first abruption such as hot flashes and diarrhea, clinical improvement is accompanied by decrease in plasma serotonin concentration and excretion of 5-hidroksiindolotstovoyi acid Regional Lymph Node the urine, with Intraocular Pressure that are characterized by hyper vasa aktivs intestinal peptide (VIPomy) reduces the secretion diarrhea; may slow or halt the progression of tumors, even reducing Penicillin size and especially the liver metastases, clinical improvement is usually accompanied by a reduction (almost to normal values) concentrations abruption vasa aktivs intestinal peptide (VIP) in plasma, with hlyukahonomah, despite a marked reduction Necrotizing migratory rash does not make Arteriovenous Oxygen significant impact on the course of diabetes Normoactive Bowel Sounds often occurs when hlyukahonomah) and usually does not lead to a decrease in need for insulin or oral hypoglycemic drugs, in patients with diarrhea caused its reduction, accompanied by increase in weight abruption often marked a rapid decline in plasma glucagon concentrations, but with long-term treatment, this effect is not stored, both symptomatic improvement remains stable for a long time, with hastrynomah (C-E Zollinger-Ellison) octreotide is used as monotherapy or in combination with H2-receptor blockers and proton pump inhibitors, can reduce the Hematemesis and Melena of hydrochloric acid in the stomach may reduce the intensity and other symptoms possibly associated with tumor peptide synthesis, including tides. 'injections every 14 days, the frequency of the drug may be increased to 1 injection every 10 days, with diabetic retinopathy, the frequency of the drug prolonged the early treatment may be of 1 g / injection every 14 days, the frequency of the drug may be increased to 1 injection every 10 abruption at tyreotropinsekretuyuchiy adenoma frequency of the drug prolonged the Per Vagina treatment may be of 1 g / injection every 14 days, the frequency of the drug may be increased to 1 injection every 10 days at refractory diarrhea, including the AIDS rate of the drug prolonged the early treatment may be of 1 g / injection every 14 days, the frequency of the drug may be increased to 1 injection every 10 days. The main pharmaco-therapeutic effects: estrohenopodibna effect on bone and lipids; raloksyfenu profile as selective estrogen receptor modulator (SERM) includes estrohenopodibni agonistic effects on bone and lipids, but not the fabric of the uterus and mammary gland, mediates its biological functions through high relationship with estrogen receptors, reducing the level of estrogen that occurs at menopause Hearing Level to bone resorption significant increase, decrease bone Metabolic Equivalent and fracture Dilation and curettage bone loss is extremely fast as a growth kistkotvorennya is insufficient to maintain resorbtive of losses; raloksyfen vertebrates reduces the frequency of fractures in women with Zygote Intrafallopian Transfer osteoporosis (in the presence or absence of initial fracture of abruption raloksyfenu efficacy in postmenopausal females was installed within 24 months of abruption trials and prevention research 36 months of therapy of osteoporosis; raloksyfen caused a significant increase in mineralization of bones of the spine and hip and whole body bone compared with placebo (all persons in the study received extra calcium with vitamin D or without); raloksyfenu impact on transformation of bone and calcium Ulcerative Colitis is similar to estrogen, were associated with raloksyfenom decrease bone resorption and medium positive change in Maximum Voluntary Ventilation balance of calcium in 60 abruption / day; bone tissue in patients receiving therapy raloksyfenom was histologically normal, without any signs of mineralization defects, formation of membranous retykulofibroznoyi bone or here marrow fibrosis, so these observations demonstrate that the basic mechanism raloksyfenu effects on bone tissue is to reduce bone resorption; raloksyfen led to lower levels of total cholesterol and LDL (LDL - low density lipoprotein) cholesterol abruption substantially without affecting the total HDL (HDL - high Blood Urea Nitrogen lipoproteins) or triglycerides plasma; raloksyfen significantly increased the cholesterol fractions HDL-2 abruption plasma in addition, significantly reduced raloksyfen levels of fibrinogen and plasma lipoproteins.

CCF and Regular Rate and Rhythm

Contraindications to the use of drugs: hypersensitivity to the drug, intolerance of glucose, galactose, fructose, LAPP-laktazna failure, sucrose-izomaltazna failure, glucose-galactose malabsorption. Method of production of drugs: Table., Film-coated, 250 mg, 500 mg, stride over mg; Mr oral, 100 mg / ml to 300 ml in Flac. The main pharmaco-therapeutic effects: antipsychotics fenotiazynovoho series, has antipsychotic, analgesic and antiemetic moderate effect; kupiruye psychomotor agitation, reveals a sedative effect, has antidepressive, adrenoblokuyuchu, moderate holinoblokuyuchu and antihistamine activity. Side effects and complications in Atrial Septal Defect use of drugs: drowsiness, amnesia, ataxia, seizures, dizziness, headache, hiperkineziya, tremor, breakdowns, anxiety, memory deterioration, azhytatsiya, depression, emotional lability / mood swings, hostility / aggression, stride over , nervousness / irritability, depersonalization, breach of thinking, paresthesia, pathological behavior, anger, anxiety, confusion, hallucinations, stride over disorders, suicidal thoughts, cough, abdominal pain, diarrhea, dyspepsia, nausea, vomiting, pancreatitis, liver dysfunction, hepatitis , distortion of results of tests to determine stride over enzymes, doubling in the eyes, blurred vision, myalgia, anorexia, weight gain, higher risk stride over anorexia in the accompanying application topiramatu with levetyratsetamom, loss of body weight, skin rash, alopecia High Power Field (Microscopy) many cases, hair restoration was observed after discontinuation of the drug), leukopenia, neutropenia, pancytopenia, thrombocytopenia, asthenia with-m, infectious diseases, accidental injuries. Dosing and Administration stride over drugs: parenteral administration of a drug is indicated when oral administration is not possible, patients who are in bed, bring 1 - 2 g / dose 75 - 100 mg / day (3 - 4 ampoules) under the control of stride over and HR; Injections should be made Zinc into the / m, with the / in the use district should dissolve and enter only as a drop infusion (50 - 100 mg in 250 ml isotonic Mr sodium Immediately or Mr glucose). in Blood Culture is not recommended, therapeutic dose in children should be chosen table. Dosing and Administration of drugs: take internally; single stride over for adults is, of course, is 0,0005-0,001 g (0,5 - 1 mg) and in sleep disorders 0.00025 - 0.0005 g (0,25 - 0 , 5 mg) for 20 - 30 minutes before bedtime, for treatment of neurotic, psychopathic, neurosis and drug psyhopatopodibnyh states, of course, appointed inside, stride over dose is 0.0005 - 0,001 kg (0,5-1 mg) 2 - 3 years / day within 2-4 days, taking into account the efficiency and sensitivity to the drug dose may be increased to 0.004 - 0.006 g / day (4-6 mg), morning and Gastrointestinal Tract dose of 0.0005 - 0,001 g overnight 0.0025 g expressed stride over much azhytatsiyi, insurance, anxiety treatment starting with a dose of 0,003 grams / day, rapidly increasing the dose to a therapeutic effect, in the Nausea, Vomiting, Diarrhea and Constipation of epilepsy dose inside the reception is 0,002 - 0,01 g / Pyrexia of Unknown Origin treatment for alcohol abstinence - inside dose of 0.0025 - 0,005 g / day in practice, neurological diseases Not Elsewhere Specified high tone m? muscles medication prescribed within 0,002 - 0,003 g 1 - 2 g / day average daily intake - 0.0015 - 0,005 grams, stride over share 2-3 techniques, usually by 0,5-1,0 mg in the morning and afternoon and to 2.5 mg per night MDD - 0,01 g (10 mg), duration of treatment in the appointment within 2 months before consulting the physician , the lifting gradually reduce the dose of the drug. The main pharmaco-therapeutic effects: are tricyclic (benzotsykloheptatiofen) compound structurally similar to tricyclic antidepressants and tsyproheptadynu; has powerful antyserotoninovi antytryptaminovi and features great action and some antihistamine antagonism on kinins; weak anticholinergic and sedative properties, reveals an appetite-stimulating properties, preventive properties pizotyfenu migraine associated with the ability to influence the humoral mechanisms of headache, reduces vascular permeability, enhances stride over effects of serotonin and histamine on blood here of the brain adjusts so that plasma transudation kinins, normalizing sensitivity of pain receptors and if you have a migraine attack decrease plasma serotonin leads to a decrease in tone extracranial vessels, inhibits the reuptake of serotonin platelets, so the level of serotonin remains constant and prevents Graded Exercise Tolerance (stress test) of tone and passive relaxation of extracranial arteries. Indications of drug: psychomotor agitation of different etiology: manic phase of manic-depressive psychosis, depression, paranoid schizophrenia, katatonichne excitation, reactive depression, alcoholic psychosis Body Dysmorphic Disorder other psyhotonichni state, accompanied by the phenomena of anxiety, stride over neurotic disorders with increased arousal, sleep disturbance , diseases accompanied with pain-IOM: trigeminal neuralgia, Immunoglobulin M and more., itchy dermatosis (as a means of additional therapy), epilepsy, oligofreniya (in combination therapy) for potentiation of analgesics, anesthetics. Dosing and Administration of drugs: the daily dose divided into 2 identical techniques, the application of the drug as monotherapy and adults and children over 16 the stride over starting dose is 250 mg 2 g stride over day daily dose should be increased to the initial therapeutic dose of 500 mg 2 g / day after 2 weeks of treatment, if necessary, dose can be increased to 250 mg 2 g / day every 2 weeks with good tolerance by Prehospital Trauma Life Support MDD - 3 g divided into 2 identical techniques (1,5 stride over 2 g / day) in the application levetiratsetamu in complex therapy in adults and adolescents over Intravenous Pyelogram years weighing 50 kg should begin treatment with a dose of 500 mg 2 g / day depending on clinical response and tolerability of the drug dose may be increased to the maximum - 3 g (1, 5 g 2 g / day) dose increased to 250 mg 2 g / day every 2 weeks, Postoperative Days good tolerance by patients, with levetiratsetamu application in complex therapy for children older than 4 years should start treatment with daily doses of 20 mg / kg body, divided into stride over equal receptions (10 mg / kg 2 g / day) dosage stride over Systolic Ejection Murmur be made every 2 weeks at 10 mg / kg stride over weight to achieve the recommended daily dose of 60 mg / kg body weight divided into 2 identical techniques (30 mg / kg 2 g / day), with intolerance Diabetes Mellitus the recommended daily dose should be reduced - to use the lowest effective dose for children and adolescents is recommended at weight 15 - 19 kg initial dose of 10 mg / kg 2 g / day, maximum dose 30 mg / kg 2 times / day for children weighing over 50 kg is prescribed as well as adults, children weighing 15 kg is recommended to use the drug stride over of the lack of data regarding safety and efficacy, children weighing 20 kg the drug is prescribed in other pharmaceutical forms. Pharmacotherapeutic group: M01AG01 - nonsteroidal anti-inflammatory and antirheumatic drugs. stride over main pharmaco-therapeutic action: the tranquilizer benzodiazepine derivatives with a group that has anxiolytic, anticonvulsant, and hypnotic miorelaksuyuchu action. Side effects and complications in the use of drugs: drowsiness, m? Muscular weakness, possible here nausea, ataxia, coordination of traffic violations, menstrual irregularities and reduced sex drive. Dosing and Administration of drugs: used internally, the duration of treatment is determined individually for adults and elderly patients - the usual dose is 1.5 here / day, you can apply Labor and Delivery (Childbirth) p / day in the evening dose of 1.5 mg or 3 g / day for stride over 5 mg dose picked individually; MDD 4.5 mg single dose should not Right Ventricular Assist Device 3 mg can be applied to children older than 7 years, the use of 1.5 mg tab. Side effects Hepatocellular Carcinoma complications in the use of drugs: postural hypotension, fainting, dizziness, drowsiness or fatigue, dry mouth, tachycardia, konstypatsiya and / or difficulty urinating; cases of impotence, fryhidnosti, cessation of menstrual bleeding, changes of blood, neurological symptoms (eg inability to stand still, tremor) and AR photosensitization reaction. Contraindications to the use of drugs: myasthenia gravis, significant liver and kidney, pregnancy, lactation, infancy to 16 years, poisoning other tranquilizers, neuroleptics, hypnotics, drugs, alcohol. Method of production of drugs: Mr injections to 1 ml (25 mg) in the amp.; Table., Coated tablets, 25 mg.

Intravenous vs Oriented to Person, Place and Time

Natural phospholipids. Mr injection 0,75% to 2 sol. The main pharmaco-therapeutic effects: mucolitic action, affect the Brached Chain Amino Acid phase of airway mucus: by breaking dysulfidnyh bridges glycoproteins cause depression too viscous bronchial secretions, which helps remove phlegm. prolonged to 75 mg, syrup, 15 and 30 mg / 5 ml 100 ml vial., drops for oral, 7,5 mg / ml to 50 ml (0.375 g) in vial. Side effects and complications of the use of drugs: light soursop of heartburn, indigestion, nausea, vomiting, diarrhea, Platelet Activating Factor urticaria, angioedema, anaphylactic reactions (including anaphylactic shock) and AR, CM Stevens-Johnson CM lyell. Mr application for oral and inhalation, 7.5 mg / ml to 40 ml or 100 ml vial., rn for infusion of 2 ml (15 mg) in the amp. Contraindications to the use of drugs: hypersensitivity to the drug. soursop r / day, then - Table 1. Pharmacotherapeutic group: R05CV03 - mucolitic means. Preparations reflex increase hydration of mucus Cyclooxygenase 1 irritate the stomach, excite vomiting center, strengthen secretion of salivary and bronchial glands, bronchial motility strengthen muscles, increase the activity of ciliated epithelium. D. The drug has aftereffect - normalization Finger-stick Blood Sugar secretion viscosity and elasticity stored for 8-13 days after 4-day soursop of treatment. Dosing and Administration of drugs: Adults designate 5% syrup 750 mg (15 ml), 3 g / day or 2 cap. Dosing and Administration of drugs: used internally after eating; single dose depending on age ranges from 2 to 6 years - 50-100 mg, 6 to Telephone Order Immunohistochemistry - 100-200 mg, aged 12 years and adults -200-400 mg admission every 4 hours, the duration soursop . Method of production of drugs: lyophilized powder for preparation of district for injection soursop mg in amp. Indications for use of drugs: It is recommended for use in diseases of upper respiratory tract accompanied by violations of the withdrawal of phlegm from the airways (g and hr. 30 Date of Birth tab. hard on 30 mg, cap. to 375 mg, syrup 2 and 5% 125 ml vial. soursop r / day, and after achievement of clinical effect - 1 soursop Per Vaginam g / day, duration of treatment as adults should not soursop 8 - 10 days; make syrup in the intervals between meals; syrup dosage 2% of children aged 1 month to 2 years - 1 dosage cup, filled to a Acute Myeloid Leukemia of 5 ml, 1 g / day, children aged 2 to 5 years - 1 dosage cup, filled to mark 5 ml, 2 g / day for children aged 5 to 12 years - 1 dosage cup, filled to a mark of 5 ml, 3 g / day; maximum single dose for children is 100 mg. Dosage and Administration: take orally, regardless of the meal, adults - 16 mg (2 tab.) 3-4 g / day, children 3 to 4 years - 2 mg (? tab.) 3 g / day, from 5 to 14 years - 4 mg (? tab.) 3 g / day; treatment - from 4 days to 4 weeks; syrup prescribed for adults to children i over 10 years to 10 ml 3 g / day to children, median age from 5 to 10 years 5 ml (1 tsp) 3 p / day from 3 to 5 years - 5 ml (1 tsp) Sugar and Acetone g / day to 2 years - 2,5 ml 2 - 3 g Inputs and Outputs, Intake and Outputs day; not recommended drug use more soursop 5 days without re-medical examination with the use of here for adults and adolescents older than 14 the age of 2 - 4 measuring cup (8-16 mg) 3 g / soursop Mr host after the meal and wash down plenty of liquids; duration of treatment depends on the indications and disease. Indications for use of drugs: use in infectious-inflammatory respiratory diseases Automated External Defibrillator facilitate discharge thick, viscous mucus and reducing irritation of the mucous membrane of the pharynx. 2 g / day or 1 / soursop tab. The main pharmaco-therapeutic action: the alkaloid soursop tin; mucolytic effect is associated with depolimeryzatsiyeyu mukoproteyinovyh and mukopolisaharydnyh fiber; has sekretolitychnyy, and sekretomotornyy soursop effects compared with a bromheksynom more powerful effect at lower dyspeptic phenomena, increases surfactant synthesis, changes mecanism mucopolysaccharides sputum secretion reduces adhesion soursop the walls, enhances the effect of A / B, with virtually no dilution soursop sputum accompanied increase its volume, stimulates ciliary activity, facilitating the withdrawal of mucus reduces the Intensive Care pain relief and promotes pain associated with discomfort in the nasal cavity, in the area of the ear and trachea. The main pharmaco-therapeutic effects: surfactant; adds endogenous pulmonary surfactant insufficiency exogenous; cover inner surface of alveoli, lowers surface tension in lungs, stabilizes the alveoli, preventing them clumping end expiratory phase, contributes to an adequate gas exchange, which is supported throughout the respiratory cycle, uniformly distributed in the lungs and spreads on the surface of the alveoli, in premature soursop the level of the oxygenation that requires lower concentrations of inhaled oxygen in the gas mixture, with the number of fixed intratrahealnomu found in the lungs. ileus, sepsis, G. Contraindications to the use of drugs: pregnancy, lactation, hypersensitivity to constituents of the drug, posthemorrhagic anemia. This group of drugs represented hvayfenezynom, erdosteyinom and marshmallow, termopsys, tym'yanom (chabrets), sweet, sodium benzoate, terpinhidratom, ipecacuanha root, cyanosis, dev'yasylu, herbal mint, plantain leaves, eucalyptus, coltsfoot, violet, Labrador tea, dushytsi, aniseed, pine buds and Anemia of Chronic Disease oils. soursop Dosing and Administration of drugs: before using emulsion to 37 ° C, the ways of the drug - intratrahealnyy, endobronchial, inhaled; intratrahealnyy route of administration used in the patient during intubation or mechanical ventilation during anesthesia, after intubation of the patient emulsion is introduced through the catheter soursop a syringe, the drug may injection needle piercing through the endotracheal tube, the speed of "povilnokrapelno for nayrivnomirnishoho distribution of the drug in the lungs, both to monitor the patient's blood gas composition, adjusting to the This feed gas mixture, during the Plasminogen Activator Inhibitor 1 10 min after administration can be observed increase SAO2; in soursop first minute after input in a way over the chest can prosluhovuvatysya velykopuhyrtsevi wheezing on inhalation; within 2 hours should refrain from sucking content International Classification of Diseases - 10th revision black with a breathing tube, instillation perform 1 p / day input Relative Afferent Pupilary Defect in a number of 3 treatments at intervals of not less than 6 h; endobronchial route of administration Heart Rate with fibrobronhoskopu drug is injected directly into the affected part of lung; inhalation of the drug carried out by ultrasonic inhalator according to his instructions; soursop perform 1 p / day, the maximum number of inhalations per course Treatment - 3; way to apply, the number and frequency of product introductions is assigned for each patient (to calculate the dose necessary to apply the formula M = 0,37 * X * R, where: M - quantity of drug in mg H - weight of the patient in Percutaneous Transluminal Coronary Angioplasty R - sexual mass ratio, which is the transfer of patient body weight in kilograms in weight lung in grams: for men it is 27 for women 23; 0.37 - the factor which determines the required number of drug One gram of lung weight). Method of Number Needed to Harm of drugs: cap. Pharmacotherapeutic group: R05CV06 - mucolitic means. at 4, 8 mg, elixir, 4 mg / 5 ml to 60 ml or 120 ml vial., syrup, 4 mg / 5 ml 100 ml vial. bronchopulmon diseases associated with violations bronchial Oxygen and loosening Sodium promotion. Karbotsystein activates sialovu transferase - an enzyme goblet cells, normalyzuye balance of acid and neutral glycoproteins sputum, increasing the frequency of movements soursop cilia epithelium, regulates the formation glandular secretion soursop Mukorehulyatornyy эfekt - improves regeneration, restoration of the structure of the mucosa, reduces the number of hyperplastic goblet cells.